Filing Flows › 10x Genomics (TXG) › Q2 2026
10x Genomics (TXG) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
10x Genomics (TXG) reported revenue of $151M for the second quarter 2026 (Q2 2026), -13% from a year earlier and +0.1% from the quarter before. Operating margin was -12.9%, net loss $17.9M (11.9% of revenue).
10x Genomics, Q2 2026: revenue $151M (-13% year over year), operating margin -12.9%, net loss $17.9M, operating cash flow $17.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $151M | +0.1% | -13% |
| Operating profit | −$19.6M | — | -165% |
| Net earnings | −$17.9M | — | -152% |
| Operating cash flow | $17.0M | -35% | -4% |
| Free cash flow | $15.4M | -37% | -5% |
What changed
Revenue was $151.0M in Q2 2026, down 13% year over year and roughly flat from the previous quarter. Single Cell was the largest line at 59% of revenue. License and royalty revenue lost $25.8M year over year (down 93%), 118% of the total change.
Gross margin was 74.5%, up 2.1 points from Q2 2025. Operating costs exceeded revenue by $19.6M, an operating margin of -12.9%. Operating expenses grew 39% against a revenue fall of 13%. The quarter ended with a net loss of $17.9M, wider than the previous quarter's $13.5M loss.
Operating cash flow was $17.0M (down 4% year over year). Non-cash charges added back $9.7M of depreciation and amortization and $25.6M of share-based compensation. Capital expenditures of $1.6M left free cash flow of $15.4M.
Questions
What was 10x Genomics' revenue in the second quarter 2026?
10x Genomics (TXG) reported revenue of $151M for the second quarter 2026 (Q2 2026), -13% from a year earlier and +0.1% from the quarter before.
Was 10x Genomics profitable in the second quarter 2026?
Operating loss was $19.6M (-12.9% of revenue) and net loss $17.9M.
Source: 10x Genomics 10-Q on SEC EDGAR.